The Cartilage Degeneration drugs in development market research report provides comprehensive information on the therapeutics under development for Cartilage Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Cartilage Degeneration. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Cartilage Degeneration and features dormant and discontinued products.
GlobalData tracks 14 drugs in development for Cartilage Degeneration by 13 companies/universities/institutes. The top development phase for Cartilage Degeneration is preclinical with six drugs in that stage. The Cartilage Degeneration pipeline has 11 drugs in development by companies and three by universities/ institutes. Some of the companies in the Cartilage Degeneration pipeline products market are: Eluciderm, Turn Biotechnologies and Generium.
The key targets in the Cartilage Degeneration pipeline products market include Transforming Growth Factor Beta (TGFb) , and Interleukin 6 Receptor Subunit Beta (Membrane Glycoprotein 130 or Oncostatin M Receptor Subunit Alpha or Interleukin 6 Signal Transducer or gp130 or CD130 or IL6ST).
The key mechanisms of action in the Cartilage Degeneration pipeline product include Transforming Growth Factor Beta (TGFB) Activator with one drug in Discovery. The Cartilage Degeneration pipeline products include three routes of administration with the top ROA being Topical and five key molecule types in the Cartilage Degeneration pipeline products market including Cell Therapy, and Small Molecule.
Cartilage Degeneration overview
Cartilage is a connective tissue of bone that protects bones and joints. Degeneration or destruction of cartilage results from both synovial-dependent and synovial-independent processes. Synovial fluid present in joints acts as a shock observer and a lubricant. Cartilage degeneration is commonly seen in osteoarthritis. OA is a degenerative inflammatory joint disease where the tissue in the joints breaks down overtime. Joint pain in hands/fingers, knees, neck, back and in hips, joint stiffness, swelling in and around the joint are the common symptoms. Age, trauma, or injury or fall, underlying diseased conditions, overweight are the common causes and is diagnosed by X-ray, MRI, other laboratory tests, physical examination to assess pain level, redness, swelling, RA factor to differentiate from rheumatoid arthritis. NSAIDS are the first line therapy for OA followed by non-pharmacological ways like hot and cold packs to relieve pain. Surgical options are chosen in complicated cases where hip replacement, knee replacement or joint replacement done.
For a complete picture of Cartilage Degeneration’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
